{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:42:25Z","timestamp":1761619345788},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1007\/s00259-007-0480-8","type":"journal-article","created":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T08:34:48Z","timestamp":1180600488000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi"],"prefix":"10.1007","volume":"34","author":[{"given":"C\u00e9lia M. F.","family":"Gomes","sequence":"first","affiliation":[]},{"given":"Mick","family":"Welling","sequence":"additional","affiliation":[]},{"given":"Ivo","family":"Que","sequence":"additional","affiliation":[]},{"given":"Niek V.","family":"Henriquez","sequence":"additional","affiliation":[]},{"given":"Gabri","family":"van der Pluijm","sequence":"additional","affiliation":[]},{"given":"Salvatore","family":"Romeo","sequence":"additional","affiliation":[]},{"given":"Antero J.","family":"Abrunhosa","sequence":"additional","affiliation":[]},{"given":"M. Filomena","family":"Botelho","sequence":"additional","affiliation":[]},{"given":"Pancras C. W.","family":"Hogendoorn","sequence":"additional","affiliation":[]},{"given":"Ernest K. J.","family":"Pauwels","sequence":"additional","affiliation":[]},{"given":"Anne Marie","family":"Cleton-Jansen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2007,6,1]]},"reference":[{"key":"480_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E","volume":"49","author":"G Rosen","year":"1982","unstructured":"Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221\u201330.","journal-title":"Cancer"},{"key":"480_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.1992.10.1.5","volume":"10","author":"PA Meyers","year":"1992","unstructured":"Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5\u201315.","journal-title":"J Clin Oncol"},{"key":"480_CR3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.1997.15.1.76","volume":"15","author":"AJ Provisor","year":"1997","unstructured":"Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children\u2019s Cancer Group. J Clin Oncol 1997;15:76\u201384.","journal-title":"J Clin Oncol"},{"key":"480_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.20.3.776","volume":"20","author":"SS Bielack","year":"2002","unstructured":"Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776\u201390.","journal-title":"J Clin Oncol"},{"key":"480_CR5","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.1998.16.7.2452","volume":"16","author":"PA Meyers","year":"1998","unstructured":"Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452\u20138.","journal-title":"J Clin Oncol"},{"key":"480_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/00043426-200311000-00006","volume":"25","author":"G Bacci","year":"2003","unstructured":"Bacci G, Forni C, Ferrari S, Longhi A, Bertoni F, Mercuri M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003;25:845\u201353.","journal-title":"J Pediatr Hematol Oncol"},{"key":"480_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0959-8049(02)00747-5","volume":"39","author":"S Smeland","year":"2003","unstructured":"Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488\u201394.","journal-title":"Eur J Cancer"},{"key":"480_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/jnci\/djk015","volume":"99","author":"IJ Lewis","year":"2007","unstructured":"Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112\u201328.","journal-title":"J Natl Cancer Inst"},{"key":"480_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev.biochem.71.102301.093055","volume":"71","author":"P Borst","year":"2002","unstructured":"Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537\u201392.","journal-title":"Annu Rev Biochem"},{"key":"480_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48\u201358.","journal-title":"Nat Rev Cancer"},{"key":"480_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"key":"480_CR12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1056\/NEJM199511233332103","volume":"333","author":"N Baldini","year":"1995","unstructured":"Baldini N, Scotlandi K, Barbantibrodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380\u20135.","journal-title":"N Engl J Med"},{"key":"480_CR13","first-page":"2461","volume":"15","author":"B Bodey","year":"1995","unstructured":"Bodey B, Taylor CR, Siegel SE, Kaiser HE. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. Anticancer Res 1995;15:2461\u20138.","journal-title":"Anticancer Res"},{"key":"480_CR14","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/jnci\/89.22.1706","volume":"89","author":"HS Chan","year":"1997","unstructured":"Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 1997;89:1706\u201315.","journal-title":"J Natl Cancer Inst"},{"key":"480_CR15","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.2000.18.14.2685","volume":"18","author":"JS Wunder","year":"2000","unstructured":"Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2000;18:2685\u201394.","journal-title":"J Clin Oncol"},{"key":"480_CR16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bjc.1998.573","volume":"78","author":"SD Shnyder","year":"1998","unstructured":"Shnyder SD, Hayes AJ, Pringle J, Archer CW. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. Br J Cancer 1998;78:757\u20139.","journal-title":"Br J Cancer"},{"key":"480_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s002590050390","volume":"26","author":"NH Hendrikse","year":"1999","unstructured":"Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283\u201393.","journal-title":"Eur J Nucl Med"},{"key":"480_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00006231-199504000-00156","volume":"16","author":"JR Ballinger","year":"1995","unstructured":"Ballinger JR, Hua HA, Berry BW, Firby P,Boxen I. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253\u20137.","journal-title":"Nucl Med Commun"},{"key":"480_CR19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1007\/s002590000375","volume":"27","author":"K Utsunomiya","year":"2000","unstructured":"Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su Z-F, et al. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000;27:1786\u201392.","journal-title":"Eur J Nucl Med"},{"key":"480_CR20","first-page":"1348","volume":"38","author":"S Del Vecchio","year":"1997","unstructured":"Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997;38:1348\u201351.","journal-title":"J Nucl Med"},{"key":"480_CR21","first-page":"228","volume":"39","author":"L Kostakoglu","year":"1998","unstructured":"Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL, et al. Association of tumor washout rates and accumulation of technetium-99\u00a0m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228\u201334.","journal-title":"J Nucl Med"},{"key":"480_CR22","first-page":"1476","volume":"42","author":"J Zhou","year":"2001","unstructured":"Zhou J, Higashi K, Ueda Y, Kodama Y, Guo D, Jisaki F, et al. Expression of multidrug resistance protein and messenger RNA correlate with 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001;42:1476\u201383.","journal-title":"J Nucl Med"},{"key":"480_CR23","first-page":"1394","volume":"44","author":"Z Burak","year":"2003","unstructured":"Burak Z, Moretti J, Ersoy O, Sanli U, Kantar M, Tamgac F, et al. 99mTc-MIBI Imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 2003;44:1394\u2013401.","journal-title":"J Nucl Med"},{"key":"480_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s002590100588","volume":"28","author":"Z Burak","year":"2001","unstructured":"Burak Z, Ersoy O, Moretti JL, Erinc R, Ozcan Z, Dirlik A, et al. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 2001;28:1341\u201350.","journal-title":"Eur J Nucl Med"},{"key":"480_CR25","first-page":"3065","volume":"7","author":"R Gorlick","year":"2001","unstructured":"Gorlick R, Liao AC, Antonescu C, Huvos AG, Healey JH, Sowers R, et al. Lack of correlation of functional scintigraphy with (99\u00a0m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Res 2001;7:3065\u201370.","journal-title":"Clin Cancer Res"},{"key":"480_CR26","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","volume":"22","author":"LA Doyle","year":"2003","unstructured":"Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340\u201358.","journal-title":"Oncogene"},{"key":"480_CR27","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1038\/sj.onc.1206953","volume":"22","author":"GD Kruh","year":"2003","unstructured":"Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537\u201352.","journal-title":"Oncogene"},{"key":"480_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.nucmedbio.2006.07.011","volume":"33","author":"CMF Gomes","year":"2006","unstructured":"Gomes CMF, Paassen H, Romeo S, Welling MM, Feitsma RIJ, Abrunhosa AJ, et al. Multidrug resistance mediated by ABC-transporters in osteosarcoma cell lines assessed by mRNA analysis and functional radiotracer studies. Nucl Med Biol 2006;33:831\u201340. DOI 10.1016\/j.nucmedbio.2006.07.011.","journal-title":"Nucl Med Biol"},{"key":"480_CR29","first-page":"4890","volume":"53","author":"O Berlin","year":"1993","unstructured":"Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 1993;53:4890\u20135.","journal-title":"Cancer Res"},{"key":"480_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.neo.7900079","volume":"2","author":"CH Contag","year":"2000","unstructured":"Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000;2:41\u201352.","journal-title":"Neoplasia"},{"key":"480_CR31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0002-9440(10)64934-6","volume":"160","author":"A Wetterwald","year":"2002","unstructured":"Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, Karperien M, et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 2002;160:1143\u201353.","journal-title":"Am J Pathol"},{"key":"480_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10585-005-0365-9","volume":"22","author":"HH Luu","year":"2005","unstructured":"Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005;22:319\u201329.","journal-title":"Clin Exp Metastasis"},{"key":"480_CR33","first-page":"454","volume":"6","author":"SK Nordeen","year":"1988","unstructured":"Nordeen SK. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques 1988;6:454\u20138.","journal-title":"Biotechniques"},{"key":"480_CR34","first-page":"1023","volume":"12","author":"E Cagliero","year":"2004","unstructured":"Cagliero E, Ferracini R, Morello E, Scotlandi K, Manara MC, Buracco P, et al. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep 2004;12:1023\u201331.","journal-title":"Oncol Rep"},{"key":"480_CR35","first-page":"545","volume":"3","author":"CC Chen","year":"1997","unstructured":"Chen CC, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 1997;3:545\u201352.","journal-title":"Clin Cancer Res"},{"key":"480_CR36","first-page":"276","volume":"58","author":"E Barbarics","year":"1998","unstructured":"Barbarics E, Kronauge JF, Cohen D, Davison A, Jones AG, Croop JM. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998;58:276\u201382.","journal-title":"Cancer Res"},{"key":"480_CR37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.nucmedbio.2005.04.014","volume":"32","author":"Z Liu","year":"2005","unstructured":"Liu Z, Stevenson GD, Barrett HH, Furenlid LR, Wilson DW, Kastis GA, et al. Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin. Nucl Med Biol 2005;32:573\u201383.","journal-title":"Nucl Med Biol"},{"key":"480_CR38","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-0829-03","volume":"10","author":"SE Bates","year":"2004","unstructured":"Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, et al. A phase I\/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 2004;10:4724\u201333.","journal-title":"Clin Cancer Res"},{"key":"480_CR39","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/cncr.21666","volume":"106","author":"WR Friedenberg","year":"2006","unstructured":"Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar\/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006;106:830\u20138.","journal-title":"Cancer"},{"key":"480_CR40","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1359\/jbmr.2001.16.6.1077","volume":"16","author":"G van der Pluijm","year":"2001","unstructured":"van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001;16:1077\u201391.","journal-title":"J Bone Miner Res"},{"key":"480_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0378-1119(97)00178-9","volume":"194","author":"G Brightwell","year":"1997","unstructured":"Brightwell G, Poirier V, Cole E, Ivins S, Brown KW. Serum-dependent and cell cycle-dependent expression from a cytomegalovirus-based mammalian expression vector. Gene 1997;194:115\u201323.","journal-title":"Gene"},{"key":"480_CR42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1096\/fj.05-4551fje","volume":"20","author":"M Krishnan","year":"2006","unstructured":"Krishnan M, Park JM, Cao F, Wang D, Paulmurugan R, Tseng JR, et al. Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J 2006;20:106\u20138.","journal-title":"FASEB J"},{"key":"480_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/pros.20003","volume":"59","author":"CD Scatena","year":"2004","unstructured":"Scatena CD, Hepner MA, Oei YA, Dusich JM, Yu SF, Purchio T, et al. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate 2004;59:292\u20133.","journal-title":"Prostate"},{"key":"480_CR44","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/01.LAB.0000036877.36379.1F","volume":"82","author":"N El Hilali","year":"2002","unstructured":"El Hilali N, Rubio N, Martinez-Villacampa M, Blanco J. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Invest 2002;82:1563\u201371.","journal-title":"Lab Invest"},{"key":"480_CR45","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jnci\/86.12.913","volume":"86","author":"Z Dong","year":"1994","unstructured":"Dong Z, Radinsky R, Fan D, Tsan R, Bucana CD, Wilmanns C, et al. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994;86:913\u201320.","journal-title":"J Natl Cancer Inst"},{"key":"480_CR46","first-page":"31","volume":"4","author":"JD Schuetz","year":"1993","unstructured":"Schuetz JD, Schuetz EG. Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell Growth Differ 1993;4:31\u201340.","journal-title":"Cell Growth Differ"},{"key":"480_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00690601","volume":"14","author":"R Radinsky","year":"1995","unstructured":"Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995;14:323\u201338.","journal-title":"Cancer Metastasis Rev"},{"key":"480_CR48","first-page":"1003","volume":"38","author":"L Kostakoglu","year":"1997","unstructured":"Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltati E, et al. Clinical validation of the influence of P-glycoprotein and technetium-99\u00a0m-sestamibi uptake in malignant tumors. J Nucl Med 1997;38:1003\u20138.","journal-title":"J Nucl Med"},{"key":"480_CR49","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/BF01084375","volume":"23","author":"JL Moretti","year":"1996","unstructured":"Moretti JL, Azaloux H, Boisseron D, Kouyoumdjian JC, Vilcoq J. Primary breast cancer imaging with technetium-99\u00a0m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 1996;23:980\u20136.","journal-title":"Eur J Nucl Med"},{"key":"480_CR50","first-page":"745","volume":"43","author":"R Sciuto","year":"2002","unstructured":"Sciuto R, Pasqualoni R, Bergomi S, Petrilli G, Vici P, Belli F, et al. Prognostic value of 99mTc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med 2002;43:745\u201351.","journal-title":"J Nucl Med"},{"key":"480_CR51","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF02439547","volume":"24","author":"S Del Vecchio","year":"1997","unstructured":"Del Vecchio S, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150\u20139.","journal-title":"Eur J Nucl Med"},{"key":"480_CR52","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s00259-005-1840-x","volume":"32","author":"JL Moretti","year":"2005","unstructured":"Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging 2005;32:836\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"480_CR53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00259-003-1381-0","volume":"31","author":"L Aloj","year":"2004","unstructured":"Aloj L, Zannetti A, Caraco C, Del Vecchio S, Salvatore M. Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. Eur J Nucl Med Mol Imaging 2004;31:521\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"480_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF03033741","volume":"10","author":"S Bruheim","year":"2004","unstructured":"Bruheim S, Bruland OS, Breistol K, Maelandsmo GM, Fodstad O. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res 2004;10:133\u201341.","journal-title":"Pathol Oncol Res"},{"key":"480_CR55","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jor.1100170502","volume":"17","author":"N Baldini","year":"1999","unstructured":"Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S, et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res 1999;17:629\u201332.","journal-title":"J Orthop Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-007-0480-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0480-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T18:44:48Z","timestamp":1630435488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-007-0480-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["480"],"URL":"https:\/\/doi.org\/10.1007\/s00259-007-0480-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]},"assertion":[{"value":"27 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"1793"}}